NCT05821933

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

An Open Single-arm Study to Evaluate the Safety, Tolerability, Efficacy of RC108 in Combination With Furmonertinib and Toripalimab in Patients With Advanced EGFR-mutated NSCLC Ib/II Study

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 106 (estimated)
• Sponsor: RemeGen Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

an open, single-arm, multicenter phase Ib/II study

Detailed description

an open, single-arm, multicenter phase Ib/II study evaluated the safety, tolerability, efficacy and pharmacokinetic profile of RC108 in combination with Furmonertinib or in combination with Furmonertinib and Toripalimab in patients with locally advanced or metastatic EGFR MET-expressing mutated NSCLC who have failed EGFR-TKI, and to develop a reasonable follow-up study for combination dosing regimens

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	RC108	RC108 plus Furmonertinib and/or Toripalimab

Timeline

• Start date: 2023-09-07
• Primary completion: 2025-09-01
• Completion: 2026-09-01
• First posted: 2023-04-20
• Last updated: 2024-04-10

Locations

1 site across 1 country: China